blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2842570

EP2842570 - COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS [Right-click to bookmark this link]
Former [2015/10]Compositions and methods for the prevention and treatment of autoimmune conditions
[2017/44]
StatusNo opposition filed within time limit
Status updated on  12.03.2021
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  03.04.2020
FormerGrant of patent is intended
Status updated on  22.10.2019
FormerExamination is in progress
Status updated on  25.07.2018
FormerGrant of patent is intended
Status updated on  22.03.2018
FormerExamination is in progress
Status updated on  24.02.2018
FormerGrant of patent is intended
Status updated on  08.10.2017
FormerExamination is in progress
Status updated on  18.04.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
UTI Limited Partnership
3655 36 Street NW
Calgary, AB T2L 1Y8 / CA
For all designated states
The General Hospital Corporation, d/b/a Massachusetts General Hospital
55 Fruit Street
Boston, Massachusetts 20114 / US
[2019/47]
Former [2019/28]For all designated states
UTI Limited Partnership
3655 36 Street NW
Calgary, AB T2L 1Y8 / CA
Former [2015/10]For all designated states
Uti Limited Partnership
Suite 130 3553 31st Street NW
Calgary, Alberta T2L 2K7 / CA
Inventor(s)01 / Santamaria, Pere
6923 Christie Estates Blvd. S.w.
Calgary, Alberta T2N 4N1 / CA
02 / Moore, Anna
200 Ledgewood Drive
Apt. 107
Stoneham, MA 02180 / US
 [2015/19]
Former [2015/10]01 / Santamaria, Pere
6923 Christie Estates Blvd. S.w.
Calgary, Alberta T2N 4N1 / CA
02 / Moore, Anna
460 Methuen Road
Dracut, MA 01826 / US
Representative(s)Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2020/19]Sagittarius IP
Marlow International
Parkway
Marlow, SL7 1YL / GB
Former [2015/10]Gibson, Mark
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
Application number, filing date14184505.707.03.2008
[2015/10]
Priority number, dateUS20070893530P07.03.2007         Original published format: US 893530 P
[2015/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2842570
Date:04.03.2015
Language:EN
[2015/10]
Type: B1 Patent specification 
No.:EP2842570
Date:06.05.2020
Language:EN
[2020/19]
Search report(s)(Supplementary) European search report - dispatched on:EP29.01.2015
ClassificationIPC:A61K39/00, A61K39/385, A61P37/00, A61P37/06, G01N33/564, G01N33/543, G01N33/569, A61K9/50
[2017/34]
CPC:
A61K39/0008 (EP,US); A61K39/385 (EP,US); A61K47/6923 (EP,US);
A61K47/6929 (EP,US); A61K9/5094 (US); A61P1/02 (EP);
A61P1/04 (EP); A61P1/16 (EP); A61P11/06 (EP);
A61P15/08 (EP); A61P17/00 (EP); A61P17/02 (EP);
A61P17/12 (EP); A61P17/14 (EP); A61P19/02 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P5/00 (EP); A61P5/14 (EP); A61P5/18 (EP);
A61P7/06 (EP); A61P9/04 (EP); G01N33/54313 (EP,US);
G01N33/564 (EP,US); G01N33/56972 (EP,US); A61K2039/55555 (EP,US);
A61K2039/572 (US); A61K2039/60 (US); A61K2039/605 (EP,US);
A61K2039/6093 (US); A61K2039/627 (US); G01N2333/70539 (EP,US);
G01N2800/042 (EP,US) (-)
Former IPC [2015/10]A61K39/00, A61K39/385, A61P37/00, A61P37/06, A61K47/48, G01N33/564, G01N33/543
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/35]
Former [2015/10]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR PRÄVENTION UND BEHANDLUNG VON AUTOIMMUNKRANKHEITEN[2017/34]
English:COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS[2017/44]
French:COMPOSITIONS ET PROCEDES POUR LA PREVENTION ET LE TRAITEMENT D'AFFECTIONS AUTO-IMMUNES[2017/34]
Former [2015/10]Zusammensetzungen und Verfahren zur Prävention und Behandlung von Autoimmunkrankheiten
Former [2015/10]Compositions and methods for the prevention and treatment of autoimmune conditions
Former [2015/10]Compositions et procédés pour la prévention et le traitement d'affections auto-immunes
Examination procedure16.07.2015Amendment by applicant (claims and/or description)
16.07.2015Examination requested  [2015/35]
22.10.2015Despatch of a communication from the examining division (Time limit: M04)
24.02.2016Reply to a communication from the examining division
19.05.2016Despatch of a communication from the examining division (Time limit: M04)
16.08.2016Reply to a communication from the examining division
31.03.2017Cancellation of oral proceeding that was planned for 10.04.2017
04.04.2017Despatch of a communication from the examining division (Time limit: M02)
10.04.2017Date of oral proceedings (cancelled)
25.05.2017Reply to a communication from the examining division
09.10.2017Communication of intention to grant the patent
19.02.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.02.2018Fee for grant paid
19.02.2018Fee for publishing/printing paid
21.03.2018Communication of intention to grant the patent
19.07.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.10.2019Communication of intention to grant the patent
05.03.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08731723.6  / EP2131856
Divisional application(s)EP17173410.6  / EP3269384
Opposition(s)09.02.2021No opposition filed within time limit [2021/15]
Fees paidRenewal fee
11.09.2014Renewal fee patent year 03
11.09.2014Renewal fee patent year 04
11.09.2014Renewal fee patent year 05
11.09.2014Renewal fee patent year 06
11.09.2014Renewal fee patent year 07
10.03.2015Renewal fee patent year 08
10.03.2016Renewal fee patent year 09
10.03.2017Renewal fee patent year 10
03.04.2018Renewal fee patent year 11
27.03.2019Renewal fee patent year 12
27.03.2020Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.03.2008
AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
PL06.05.2020
RO06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
TR06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
[2024/29]
Former [2023/27]HU07.03.2008
AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
PL06.05.2020
RO06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2023/24]AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
PL06.05.2020
RO06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/45]AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
PL06.05.2020
RO06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/24]AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
PL06.05.2020
RO06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/10]AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
PL06.05.2020
RO06.05.2020
SE06.05.2020
SK06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/09]AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
IT06.05.2020
LT06.05.2020
LV06.05.2020
RO06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/08]DK06.05.2020
ES06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RO06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/01]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/50]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
SE06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/48]FI06.05.2020
LT06.05.2020
SE06.05.2020
NO06.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/47]LT06.05.2020
NO06.08.2020
IS06.09.2020
Former [2020/46]IS06.09.2020
Documents cited:Search[I]US2003068363  (CLARK BRIAN R [US], et al) [I] 9-14* the whole document *;
 [Y]WO2004078909  (FRAUNHOFER GES FORSCHUNG [DE], et al) [Y] 1-8,15 * claims 115,128 * * page 9, line 24 - page 11, line 24 *;
 [YD]  - MOORE ANNA ET AL, "Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time", DIABETES, (200406), vol. 53, no. 6, ISSN 0012-1797, pages 1459 - 1466, XP002499320 [YD] 1-8,15 * the whole document *

DOI:   http://dx.doi.org/10.2337/diabetes.53.6.1459
ExaminationUS2005003431
by applicantUS4367110
 US4414148
 US4452901
 US4554101
 US4569789
 US4589071
 US4589330
 EP0188256
 US4659839
 US4671958
 US4680338
 US4699784
 US4818542
 US5543391
 US6103379
 US6387498
 US6651655
 US6688494
 US6712997
 US6846474
 US6929675
 US2005202032
 US7060121
 US7186814
 US2007059775
 US7326399
 US7332586
    - AICHELE ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 444 - 448
    - AMRANI ET AL., J. IMMUNOLOGY, (2001), vol. 167, pages 655 - 666
    - AMRANI ET AL., NATURE, (2000), vol. 406, pages 739 - 742
    - ANDERSON ET AL., PROC. NATL. ACAD. SCI. USA, (1999), vol. 96, pages 9311 - 9316
    - ANDERTON; WRAITH, EUR. J. IMMUNOL., (1998), vol. 28, pages 1251 - 1261
    - ARDEN ET AL., DIABETES, (1999), vol. 48, pages 531 - 539
    - ATKINSON; MACLAREN, N. ENGL. J. MED., (1994), vol. 331, pages 1428 - 1436
    - ATKINSON; MACLAREN, SCI. AM., (1990), vol. 7, pages 62 - 67
    - BARANY; MERRIFIELD, The Peptides, ACADEMIC PRESS, (1979), pages 1 - 284
    - BIELEKOVA ET AL., NAT. MED., (2000), vol. 6, pages 1167 - 1175
    - BOTTAZZO, N. ENGL. J. MED., (1985), vol. 313, pages 353 - 360
    - BURKE ET AL., J. INF. DIS., (1994), vol. 170, pages 1110 - 1119
    - CAO ET AL., HUM. IMMUNOL., (2001), vol. 62, page 1009
    - CARUSO ET AL., MACROMOLECULES, (1999), vol. 32, no. 7, pages 2317 - 2328
    - CARUSO, J. AMER. CHEM. SOC., (1999), vol. 121, no. 25, pages 6039 - 6046
    - CASTANO; EISENBARTH, ANNU. REV. IMMUNOL., (1990), vol. 8, pages 647 - 679
    - CHENTOUFI; POLYCHRONAKOS, DIABETES, (2002), vol. 51, page 1383
    - CHOU; FASMAN, ADV. ENZYMOL., (1978), vol. 47, pages 45 - 148
    - CHOU; FASMAN, ANNU. REV. BIOCHEM., (1978), vol. 47, pages 251 - 276
    - CHOU; FASMAN, BIOCHEMISTRY, (1974), vol. 13, no. 2, pages 211 - 222
    - CHOU; FASMAN, BIOCHEMISTRY, (1974), vol. 13, no. 2, pages 222 - 245
    - CHOU; FASMAN, BIOPHYS. J., (1979), vol. 26, no. 3, pages 385 - 399
    - DAVIES, ADVANCED MATERIALS, (1998), vol. 10, pages 1264 - 1270
    - DILORENZO, PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 12538 - 12543
    - DOYTCHINOVA ET AL., J. IMMUNOL., (2004), vol. 172, page 4314
    - FENNESSY ET AL., DIABETOLOGIA, (1994), vol. 37, pages 937 - 945
    - GOLMAN; SHINOHARA, TRENDS CHEM. ENGIN., (2000), vol. 6, pages 1 - 6
    - GOULDER ET AL., J. EXP. MED., (2000), vol. 192, pages 1819 - 1832
    - GROUP, D.P.T.-T.D.S, N. ENGL. J. MED., (2002), vol. 346, pages 1685 - 1691
    - HALLER ET AL., N. ENGL. J. MED., (2005), vol. 353, pages 2086 - 2087
    - HAMILTON-WILLIAMS ET AL., PROC. NATL. ACAD. SCI. USA, (2001), vol. 98, page 11533
    - HAN ET AL., J. CLIN. INVEST., (2005), vol. 115, page 1879
    - HAN ET AL., NAT. MED., (2005), vol. 11, pages 645 - 652
    - HANNINEN ET AL., J. CLIN. INVEST., (1992), vol. 90, pages 1901 - 1910
    - HANPRASOPWATTANA, LANGMUIR, (1996), vol. 12, pages 3173 - 3179
    - HONEYMAN ET AL., MOL. MED., (1995), vol. 1, no. 5, pages 576 - 582
    - IMAGAWA ET AL., DIABETES, (2001), vol. 50, pages 1269 - 1273
    - ITOH, J. CLIN. INVEST., (1993), vol. 92, pages 2313 - 2322
    - KAPPOS ET AL., NAT. MED., (2000), vol. 6, pages 1176 - 1182
    - KARIN ET AL., J. EXP. MED., (1994), vol. 180, pages 2227 - 2237
    - KENT ET AL., NATURE, (2005), vol. 435, pages 224 - 228
    - KEYMEULEN ET AL., N. ENGL. J. MED., (2005), vol. 352, no. 25, pages 2598 - 608
    - KREUTER, Colloidal Drug Delivery Systems, MARCEL DEKKER, INC., (1994), pages 219 - 342
    - LIBLAU ET AL., IMMUNITY, (2002), vol. 17, pages 1 - 6
    - LIEBERMAN; DILORENZO, TISSUE ANTIGENS, (2003), vol. 62, pages 359 - 377
    - LIEBERMAN ET AL., J. IMMUNOL., (2004), vol. 173, page 6727
    - LIEBERMAN ET AL., PROC. NATL. ACAD. SCI. USA, (2003), vol. 100, pages 8384 - 8388
    - LIU; WRAITH, INT. IMMUNOL., (1995), vol. 7, pages 1255 - 1263
    - MAREE ET AL., INT. IMMUNOL., (2006), vol. 18, pages 1067 - 1077
    - MARTIN ET AL., J. BIOL. CHEM., (2001), vol. 276, pages 25197 - 25207
    - MCKOWN ET AL., ARTHRITIS RHEUM., (1999), vol. 42, pages 1204 - 1208
    - MERRIFIELD, SCIENCE, (1986), vol. 232, no. 4748, pages 341 - 347
    - METZLER; WRAITH, INT. IMMUNOL., (1993), vol. 5, pages 1159 - 1165
    - MILLER ET AL., J. EXP. MED., (1979), vol. 149, pages 758 - 766
    - MOORE, DIABETES, (2004), vol. 53, pages 1459 - 1466
    - MORIWAKI ET AL., DIABETOLOGIA, (1999), vol. 42, pages 1332 - 1340
    - NAKANISHI ET AL., J. CLIN. ENDOCRINOL. METAB., (1999), vol. 84, pages 3721 - 3725
    - NAKAYAMA ET AL., NATURE, (2005), vol. 435, pages 220 - 224
    - NEJENTSEV ET AL., DIABETES, (1997), vol. 46, pages 1888 - 1895
    - OWERBACH, DIABETES, (2000), vol. 49, pages 508 - 512
    - PALMER ET AL., SCIENCE, (1983), vol. 222, pages 1337 - 1339
    - PARTCH; BROWN, J. ADHESION, (1998), vol. 67, pages 259 - 276
    - PASCOLO ET AL., J. EXP. MED., (1997), vol. 185, page 2043
    - PEKAREK ET AL., NATURE, (1994), vol. 367, page 258
    - PINKSE ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 18425 - 18430
    - POCIOT; MCDERMOTT, GENES IMMUN., (2002), vol. 3, pages 235 - 249
    - POZZILLI ET AL., DIABETOLOGIA, (2000), vol. 43, pages 1000 - 1004
    - ROBLES ET AL., CLIN. IMMUNOL., (2002), vol. 102, pages 117 - 224
    - SANTAMARIA ET AL., DIABETES, (1992), vol. 41, pages 53 - 61
    - SANTAMARIA ET AL., J. IMMUNOL., (1995), vol. 154, page 2494
    - SANTAMARIA, CURR. OPIN IMMUNOL., (2001), vol. 13, pages 663 - 669
    - SERREZE ET AL., DIABETES, (1994), vol. 43, page 505
    - SERREZE, DIABETES, (2001), vol. 50, pages 1992 - 2000
    - SIBLEY ET AL., LAB. INVEST., (1985), vol. 53, pages 132 - 144
    - SIDNEY ET AL., HUM. IMMUNOL., (1996), vol. 45, page 79
    - SOMOZA ET AL., J. IMMUNOL., (1994), vol. 153, pages 1360 - 1377
    - SUKHORUKOV ET AL., POLYMERS ADV. TECH., (1998), vol. 9, no. 10-11, pages 759 - 767
    - TAIT, HUM. IMMUNOL., (1995), vol. 42, pages 116 - 124
    - TAKAKI ET AL., J. IMMUNOL., (2006), vol. 176, pages 3257 - 3265
    - TAM ET AL., J. AM. CHEM. SOC., (1983), vol. 105, page 6442
    - TAN ET AL., J. EXP. MED., (2002), vol. 12, pages 1523 - 1532
    - TICE; TABIBI, Treatise on Controlled Drug Delivery, MARCEL DEKKER, INC., (1992), pages 315 - 339
    - TIGGES ET AL., J. IMMUNOL., (1996), vol. 156, no. 10, pages 3901 - 3910
    - TOES ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 7855 - 7860
    - TOMA ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 10581 - 10585
    - TRENTHAM ET AL., SCIENCE, (1993), vol. 261, pages 1727 - 1730
    - TRUDEAU ET AL., J. CLIN. INVEST., (2003), vol. 111, pages 217 - 223
    - VERDAGUER ET AL., J IMMUNOTOGY, (1996), vol. 157, pages 4726 - 4735
    - VERDAGUER ET AL., J. EXP. MED., (1997), vol. 186, pages 1663 - 1676
    - WEINER, SCIENCE, (1993), vol. 259, pages 1321 - 1324
    - WONG ET AL., NAT. MED., (1999), vol. 5, pages 1026 - 1031
    - WRAITH ET AL., CELL, (1989), vol. 59, pages 247 - 255
    - YEAMAN ET AL., ANN. NYACAD. SCI., (2002), vol. 955, pages 174 - 182
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.